Stocks · News reference

Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook

Aug 7, 2026, 6:35 PMVandana Singh

Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue outlook bump.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 27, 2026, 10:08 AMBenzinga Newsdesk
Natera Announces Signatera Collaboration With Angiex To Develop A Portfolio Of Nuclear-Delivered Antibody-Drug Conjugates
Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated
Read original at benzinga
NTRA
BenzingaAug 13, 2026, 7:50 PMBenzinga Newsdesk
Citigroup Maintains Buy on Natera, Raises Price Target to $365
Citigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $315 to $365.
Read original at benzinga
NTRA
BenzingaAug 12, 2026, 4:26 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on Natera, Raises Price Target to $363.5
Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $249 to $363.5.
Read original at benzinga
NTRA
BenzingaAug 12, 2026, 4:20 PMBenzinga Newsdesk
Stephens & Co. Maintains Overweight on Natera, Raises Price Target to $350
Stephens & Co. analyst Mason Carrico maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $305 to $350.
Read original at benzinga
NTRA